menu
    • menu

    Company profile for Dana-Farber Cancer Institute

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    With Virupaksha, you get a quality product with on-time delivery.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2025-11-24

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    ChemExpress delivers end-to-end CRO & CDMO solutions for small molecules, biologics & new modalities with ICH-grade quality.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Since its founding in 1947, Dana-Farber Cancer Institute in Boston, Massachusetts has been committed to providing adults and children with cancer with the best treatment available today while developing tomorrow's cures through cutting-edge research. Read about our history, our breakthroughs, and the resources that help us support the health of our neighborhoods and communities.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Dana-Farber Cancer InstituteUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    450 Brookline Avenue Boston, MA 02215
    Telephone
    Telephone
    617-632-3000
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.dana-farber.org/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DDL Conference

    Not Confirmed

    envelop Contact Supplier

    DDL Conference

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Cancer vaccine prevents kidney cancer comeback in small trial
    Cancer vaccine prevents kidney cancer comeback in small trial

    07 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/cancer-vaccine-prevents-recurrence-advanced-kidney-cancer-small-trial

    FIERCE BIOTECH
    07 Feb 2025
    Share Share
    Fortress Biotech Doses First Patient In Phase 2 Triplex Trial
    Fortress Biotech Doses First Patient In Phase 2 Triplex Trial

    27 Jan 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/01/27/3015614/28889/en/Fortress-Biotech-Announces-First-Patient-Dosed-in-Phase-2-Clinical-Trial-of-Triplex-Vaccination-in-Stem-Cell-Donors-to-Reduce-CMV-Events-in-Recipients-of-HSCT.html

    GLOBENEWSWIRE
    27 Jan 2025
    Share Share
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax
    Lisaftoclax in Combo Shows Potential in Exposed to Venetoclax

    10 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/live-from-ash-2024--ascentage-pharmas-bcl-2-inhibitor-lisaftoclax-in-combinations-demonstrates-potential-clinical-benefit-in-patients-with-prior-exposure-to-venetoclax-302327542.html

    PR NEWSWIRE
    10 Dec 2024
    Share Share
    invIOs Raises €8.2 Million In Series A For Immuno-Oncology
    invIOs Raises €8.2 Million In Series A For Immuno-Oncology

    15 Oct 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/10/15/2962950/0/en/invIOs-raises-8-2-million-in-a-Series-A-to-finance-pipeline-progress-in-immuno-oncology.html

    GLOBENEWSWIRE
    15 Oct 2024
    Share Share
    eFFECTOR, Dana-Farber To Study Zotatifin ER+ Endo/Ovarian Cancer Combo
    eFFECTOR, Dana-Farber To Study Zotatifin ER+ Endo/Ovarian Cancer Combo

    20 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/20/2884841/0/en/eFFECTOR-Therapeutics-to-Collaborate-with-the-Dana-Farber-Cancer-Institute-on-an-Investigator-Sponsored-Phase-2-Clinical-Trial-Evaluating-Zotatifin-as-Combination-Treatment-in-ER-E.html

    GLOBENEWSWIRE
    20 May 2024
    Share Share
    Dana-Farber’s computer platform makes patient matching process easier
    Dana-Farber’s computer platform makes patient matching process easier

    14 Oct 2022

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/dana-farbers-patient-matching-process/

    CLINICALTRIALSARENA
    14 Oct 2022
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search